Overall, the mutational load was higher in relapse MM and aberrations previously linked to MM resurfaced in both primary pretreatment and relapse tumours in our cohort, including mutations in RAS genes, DIS3, TP53, FGFR3, and PAX5 CRE mutations. The gene discussed is TP53; the disease is Miyoshi myopathy.